To assess the demographic characteristics of the 1902 transthyretin amyloid cardiomyopathy patients treated by tafamidis through the French early access program
Latest Information Update: 01 Dec 2021
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
- Focus Expanded access; Therapeutic Use
- 01 Dec 2021 New trial record